(Reuters) – Spanish healthcare firm Grifols (NSDQ:GRFS) said today that it was given the green light to go ahead with a new blood plasma installation in Clayton, N.C., by the FDA.

The plant will increase Grifol’s plasma fractionation capacity by 6 million liters of plasma a year, almost doubling total global capacity, it said in a regulatory filing.

Barcelona-based Grifols has invested over $370 million in the Clayton plant, which employs more than 200 people, since it was opened in 2010.